Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07214662) titled 'A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer' on Oct. 3.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Genentech, Inc.
Condition:
Breast Cancer
Intervention:
Drug: GDC-0587
Drug: Giredestrant
Recruitment Status: Not recruiting
Phase:...